Promising Leap Forward in Research on PSC and Bile Duct Cancer
Promising Leap Forward in Research on PSC and Bile Duct Cancer
Dr Edward Jarman
We are pleased to share an important update from the research project, 'Cell states in the transition from PSC to bile duct cancer,' led by Dr Edward Jarman. This study, which we proudly fund, focuses on a critical area: understanding the changes that occur when PSC progresses to cholangiocarcinoma (CCA), a type of bile duct cancer.
The team has been using advanced laboratory modelling to observe this complex process. Through this, they have successfully identified a distinct 'signature' (a pattern of cell changes) that happens during the transition.
A key finding is the identification of a protein called COX2 as a potential marker of this process. In a significant step, Dr Jarman has shown that a subset of PSC patients have cells that are positive for COX2 in their bile ducts. This finding is crucial because it means that what the scientists are seeing in the lab matches what is actually happening inside the bodies of people with PSC.
Dr Jarman notes that this represents an ‘appreciable leap forward’ for the project’s goal to define the mechanisms of PSC-CCA transition and determine whether these early changes are detectable in PSC patients.
This work is an exciting step forward. By defining these mechanisms and identifying markers like COX2, this research may eventually help us to detect early changes in people with PSC who could be at higher risk. This is vital for accelerating the development of new ways to screen, prevent, or treat the progression to CCA.
Turning Ambition into Action in 2026:
Our Fortnight in Focus
At PSC Support, we want a world without PSC. We work tirelessly behind the scenes to drive research and improve lives. Here is a snapshot of what we've been up to:
Organisational excellence: We simplified our personal data consent process and streamlined how we record patient stories to ensure that the lived experiences of our community are captured accurately and securely to inform future work.
Progressing Research: We coordinated a series of upcoming meetings with international researchers and pharmaceutical companies, which supports better informed decisions for people with PSC, research, or care. This groundwork helps keep PSC research focused on the primary needs of the patient community.
Progressing Research: We reviewed and contributed to scientific abstracts and posters for the upcoming EASL international liver congress, which strengthens the quality of future research for people with PSC, research, or care.
Progressing Research: We engaged with the MHRA to prepare for the upcoming national consultation on rare disease therapies, representing PSC patients in the wider community. Maintaining this direct dialogue ensures our organisation is prepared to respond formally and protect the interests of those living with PSC
Improving Care: We presented about what it is really like to live with PSC to gastroenterologists This first-hand insight equips healthcare professionals to better understand the day-to-day challenges of PSC.
Income Generation: We secured a place in the prestigious Big Give Small Charity Week match-funding campaign, so that we can maximise future donations from our supporters as every donation between 22 and 29 June will be doubled!
Progressing Research: We recruiting for a research and advocacy officer to expand our core team. This additional capacity ensures we can better support scientific studies and represent the patient voice at every level.